Merck (MRK) And Ridgeback Announce Publication of Phase 3 Study of Molnupiravir

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. QQQ
8. LDOS
9. HUM
10. KTOS

Go back to Merck (MRK) And Ridgeback Announce Publication of Phase 3 Study of Molnupiravir

Daiwa Securities Starts Merck (MRK) at Neutral (3)

December 16, 2021 4:25 AM EST

Daiwa Securities initiates coverage on Merck (NYSE: MRK) with a Neutral (3) rating and a price target of $70.00.


For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.


Shares of Merck closed at $75.29 yesterday.

... More

Merck's (MRK) VAXNEUVANCE Approved in the EU for Individuals 18 Years of Age and Older

December 15, 2021 6:45 AM EST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the European Commission (EC) has approved VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. The approval allows marketing of VAXNEUVANCE in all 27 European Union (EU) Member States plus Iceland, Norway and Lichtenstein. The use of VAXNEUVANCE in the EU should be in accordance with official recommendations.

The ECs decision follows a positive opinion from the European Medicines Agencys... More